Valuation: Rezolute, Inc.

Market Cap 41Cr 37Cr 34Cr 31Cr 58Cr 3.93TCr 59Cr 407.05Cr 163.4Cr 2.07TCr 155.5Cr 152.19Cr 6.53TCr P/E 2027 *
-5.59x
P/E 2028 * -7.64x
Enterprise Value 41Cr 37Cr 34Cr 31Cr 58Cr 3.93TCr 59Cr 407.05Cr 163.4Cr 2.07TCr 155.5Cr 152.19Cr 6.53TCr EV / Sales 2027 *
198x
EV / Sales 2028 * 7.66x
Free-Float
89.97%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Rezolute, Inc.

1 day-4.13%
1 week+2.46%
1 month-4.59%
3 months-16.31%
6 months+23.44%
Current year+67.37%
1 week 3.73
Extreme 3.73
4.33
1 month 3.37
Extreme 3.37
4.91
Current year 1.87
Extreme 1.87
5.64
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
70
Manager TitleAgeSince
Chief Executive Officer 59 30/01/2013
Director of Finance/CFO 53 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 59 04/05/2022
Chairman 70 10/02/2019
Director/Board Member 55 20/11/2019
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Tax

Executive/Senior Manager

-2,267 0.0024%
02/07/26 Tax

Chief Technology Officer

-3,062 0.0035%
02/07/26 Tax

Chief Financial Officer

-3,062 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
-4.13%+2.46%-57.62%+315.79% 41Cr
-0.62%-1.87%+42.87%+64.15% 6.38TCr
+0.35%+3.20%+14.92%+84.55% 5.64TCr
+0.53%+1.96%+15.37%+106.81% 5.46TCr
-2.81%-4.31%+23.50%+47.83% 4.41TCr
-0.33%-1.93%+19.28%+98.80% 4.21TCr
+0.55%+2.31%+225.14%+866.21% 4.1TCr
+3.27%+47.96%+112.67%+96.48% 3.49TCr
+1.22%-1.44%+14.89%+47.15% 3.28TCr
+0.89%+20.55%-40.62%+349.24% 2.47TCr
Average -0.11%+7.03%+37.04%+207.70% 3.95TCr
Weighted average by Cap. +0.17%+5.44%+47.85%+177.70%

Financials

2027 *2028 *
Net sales 20.95L 18.76L 17.26L 15.64L 29.23L 20Cr 29.77L 2.06Cr 82.61L 10Cr 78.61L 76.94L 33Cr 5.41Cr 4.84Cr 4.46Cr 4.04Cr 7.55Cr 513.58Cr 7.69Cr 53Cr 21Cr 270.16Cr 20Cr 20Cr 851.98Cr
Net income -7.95Cr -7.12Cr -6.55Cr -5.93Cr -11Cr -754.72Cr -11Cr -78Cr -31Cr -397.01Cr -30Cr -29Cr -1.25TCr -5.99Cr -5.37Cr -4.94Cr -4.47Cr -8.36Cr -569.05Cr -8.52Cr -59Cr -24Cr -299.34Cr -22Cr -22Cr -944Cr
Net Debt - -
Projected Income Statement - Annual - Rezolute, Inc.
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
58
Date Price Change Volume
30/26/30 $3.950 -4.13% 7,79,252
29/26/29 $4.120 -2.37% 7,56,259
28/26/28 $4.220 +2.68% 14,14,535
27/26/27 $4.110 +7.59% 14,00,114
26/26/26 $3.820 -0.91% 15,43,500
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rezolute, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.950USD
Average target price
9.800USD
Spread / Average Target
+148.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rezolute, Inc.
  1. Stock Market
  2. Stocks
  3. RZLT Stock